Related Experiment Videos
Antitumour prodrug development using cytochrome P450 (CYP) mediated activation
L H Patterson1, S R McKeown, T Robson
1Department of Pharmaceutical and Biological Chemistry, School of Pharmacy, University of London, UK. medchem@cub.ulsop.ac.uk
Anti-Cancer Drug Design
|June 2, 2000
Summary
This study demonstrates that the chemotherapeutic prodrug AQ4N is activated by cytochrome P450 3A (CYP3A) enzymes under hypoxic conditions, generating its cytotoxic metabolite AQ4. This targeted activation in tumors offers a promising strategy for cancer therapy.
Area of Science:
- Biochemistry
- Pharmacology
- Oncology
Background:
- Cancer chemotherapeutic prodrugs ideally require tumor-specific activation.
- Cytochrome P450 (CYP) isoforms, including CYP3A, are expressed in various human cancers.
- Hypoxic tumor microenvironments present an opportunity for targeted prodrug activation.
Purpose of the Study:
- To investigate the potential of CYP isoforms for tumor-specific prodrug activation.
- To evaluate AQ4N, a prodrug activated by CYP3A, for its bioreductive activation in hypoxic tumor regions.
- To elucidate the mechanism and conditions governing AQ4N activation.
Main Methods:
- Assessed the 4-electron reduction of AQ4N to its cytotoxic metabolite AQ4 by murine mammary carcinoma and fibrosarcoma.
- Investigated the role of NADPH, air, and carbon monoxide in prodrug conversion.
- Quantified CYP3A mRNA and protein levels in tumor cells under varying oxygen conditions.
- Confirmed CYP3A4-mediated activation using human lymphoblastoid cell microsomes.
- Evaluated AQ4N reduction in human renal cell carcinoma and normal kidney tissues.
Main Results:
- Murine tumor cells and human renal cells reduced AQ4N to AQ4, dependent on NADPH and low oxygen.
- CYP3A protein levels increased in tumor cells exposed to anoxia, while mRNA levels initially decreased.
- CYP3A4-transfected cells, but not CYP2B6-transfected cells, activated AQ4N.
- Both normal and tumor kidney cells reduced AQ4N, but only under hypoxic conditions.
Conclusions:
- CYP3A enzymes are key mediators of AQ4N bioreductive activation to its cytotoxic form.
- Hypoxia in tumor microenvironments is crucial for AQ4N activation, suggesting tumor-specific prodrug therapy.
- The stabilization of CYP3A protein under anoxia enhances its role in targeted cancer chemotherapy.